Spinardi Júlia, Dantas Ana Carolina, Carballo Carolina, Thakkar Karan, Akoury Nadine Al, Kyaw Moe Hein, Del Carmen Morales Castillo Graciela, Srivastava Amit, Sáfadi Marco Aurélio P
Vaccine Medical and Scientific Affairs, Pfizer, Rua Alexandre Dumas, 1860, São Paulo, 04717904, Brazil.
Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.
Infect Dis Ther. 2023 May;12(5):1237-1264. doi: 10.1007/s40121-023-00804-2. Epub 2023 Apr 25.
The rapid rollout of vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic over the past 2 years has resulted in the use of various vaccine platforms and regional differences in COVID-19 vaccine implementation strategies. The aim of this narrative review was to summarize evolving COVID-19 vaccine recommendations in countries in Latin America, Asia, and Africa and the Middle East across various vaccine platforms, age groups, and specific subpopulations. Nuances in primary and booster vaccination schedules were evaluated, and the preliminary impact of such diverse vaccination strategies are discussed, including key vaccine effectiveness data in the era of Omicron-lineage variants. Primary vaccination rates for included Latin American countries were 71-94% for adults and between 41% and 98% for adolescents and children; rates for first booster in adults were 36-85%. Primary vaccination rates for adults in the included Asian countries ranged from 64% in the Philippines to 98% in Malaysia, with corresponding booster rates varying from 9% in India to 78% in Singapore; for adolescents and children, primary vaccination rates ranged from 29% in the Philippines to 93% in Malaysia. Across included African and Middle Eastern countries, primary vaccination rates in adults varied widely from 32% in South Africa to 99% in the United Arab Emirates; booster rates ranged from 5% in South Africa to 60% in Bahrain. Evidence from the regions studied indicates preference of using an mRNA vaccine as a booster on the basis of safety and effectiveness of observed real-world data, especially during circulation of Omicron lineages. Vaccination against COVID-19 remains of paramount importance to reduce the burden of disease; strategies to overcome vaccine inequity, fatigue, hesitancy, and misinformation and to ensure adequate access and supply are also important.
在过去两年里,为抗击2019冠状病毒病(COVID-19)大流行而迅速推出的疫苗导致了多种疫苗平台的使用以及COVID-19疫苗实施策略的地区差异。本叙述性综述的目的是总结拉丁美洲、亚洲、非洲和中东各国在不同疫苗平台、年龄组和特定亚人群中不断演变的COVID-19疫苗建议。评估了初次和加强疫苗接种计划的细微差别,并讨论了这种多样化疫苗接种策略的初步影响,包括奥密克戎谱系变体时代的关键疫苗有效性数据。纳入研究的拉丁美洲国家成年人的初次疫苗接种率为71%-94%,青少年和儿童的接种率在41%至98%之间;成年人的首次加强接种率为36%-85%。纳入研究的亚洲国家成年人的初次疫苗接种率从菲律宾的64%到马来西亚的98%不等,相应的加强接种率从印度的9%到新加坡的78%不等;青少年和儿童的初次疫苗接种率从菲律宾的29%到马来西亚的93%不等。在纳入研究的非洲和中东国家中,成年人的初次疫苗接种率差异很大,从南非的32%到阿拉伯联合酋长国的99%;加强接种率从南非的5%到巴林的60%不等。来自所研究地区的证据表明,根据观察到的真实世界数据的安全性和有效性,尤其是在奥密克戎谱系传播期间,倾向于使用mRNA疫苗作为加强针。接种COVID-19疫苗对于减轻疾病负担仍然至关重要;克服疫苗不平等、疲劳、犹豫和错误信息以及确保充足的获取和供应的策略也很重要。